Claims
- 1. A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 2. A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 3. A method of inhibiting dendritic cell-induced B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 4. A method of treatment of an autoimmune disease comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 5. A method of treating hypertension in an animal comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 6. A method of treating renal disorders in an animal comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 7. A method of treating B-cell lympho-proliferate disorders comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof; (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and (c) an anti-BAFF-R antibody homolog.
- 8. A method according to claims 1 to 7, wherein the BAFF-R polypeptide is soluble.
- 9. The method according to claim 8, wherein the soluble BAFF-R polypeptide comprises a BAFF-R extracellular domain.
- 10. The method of claim 9 wherein the BAFF-R extracellular domain is fused to an immunoglobulin.
- 11. A method according to claims 1 to 7, wherein the BAFF-R polypeptide is selected from the group consisting of:
a) an isolated native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:1 or a fragment thereof; b) an isolated BAFF-R polypeptide having at least 80% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof; c) an isolated BAFF-R polypeptide having at least 90% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof; d) an isolated BAFF-R polypeptide comprising amino acid residues 1 to 51 of SEQ ID NO: 1 or a fragment thereof; and e) an isolated BAFF-R polypeptide comprising amino acid residues 8 to 41 of SEQ ID NO: 1 or a fragment thereof.
- 12. A method according to claims 1 to 7, wherein the anti-BAFF-R antibody homolog is a monoclonal antibody.
- 13. A method according to claims 1 to 7, wherein the anti-BAFF-R antibody homolog comprises BCMA-IgG.
- 14. A method according to claims 1 to 7, wherein the animal is a mammal.
- 15. The method according to claim 14, wherein the mammal is human.
- 16. A method of treating, suppressing or altering an immune response involving a signaling pathway between a BAFF-R and BAFF comprising the step of administering an effective amount of an agent capable of interfering with the association between the BAFF-R and BAFF.
- 17. A method of inhibiting inflammation comprising the step of administering a therapeutically effective amount of an antibody specific for a BAFF-R or an active fragment thereof.
- 18. A method of inhibiting inflammation comprising the step of administering a therapeutically effective amount of an antibody specific for a BAFF-R or an epitope thereof.
- 19. A pharmaceutical composition comprising a therapeutically effective amount of an isolated BAFF-R polypeptide or a fragment thereof and a pharmaceutically acceptable carrier.
- 20. The pharmaceutical composition of claim 19 wherein the isolated BAFF-R polypeptide is selected from the group consisting of:
a) an isolated native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:1 or a fragment thereof; b) an isolated BAFF-R polypeptide having at least 80% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof; c) an isolated BAFF-R polypeptide having at least 90% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof; d) an isolated BAFF-R polypeptide comprising amino acid residues 1 to 51 of SEQ ID NO: 1 or a fragment thereof; and e) an isolated BAFF-R polypeptide comprising amino acid residues 8 to 41 of SEQ ID NO: 1 or a fragment thereof.
- 21. The pharmaceutical composition of claim 19 wherein the BAFF-R polypeptide fragment comprises a BAFF-R extracellular domain fused to an imunoglobulin.
RELATED APPLICATIONS
[0001] This is a continuation of PCT/US00/22507, filed on Aug. 16, 2000, which claims priority from U.S. provisional application Serial No. 60/149,378 filed on Aug. 17, 1999, U.S. provisional application Serial No. 60/181,684 filed on Feb. 11, 2000 and U.S. provisional application Serial No. 60/183,536 filed on Feb. 18, 2000.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60149378 |
Aug 1999 |
US |
|
60181684 |
Feb 2000 |
US |
|
60183536 |
Feb 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/22507 |
Aug 2000 |
US |
Child |
10077137 |
Feb 2002 |
US |